Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JLP-2002 (Vibegron) in Patients With Overactive Bladder
NCT04917315Phase 3Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- May 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder (OAB) comparing JLP-2002 (Vibegron) with Placebo (2 arms). Primary endpoint: Change From Baseline in Average Daily Micturitions at 12 weeks. Started May 2020; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT04917315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917315.